The suggested dosage for testosterone cypionate injection, USP, varies depending on the individual patient's age, sex, and diagnosis. The dose is adjusted according to the patient's response and the occurrence of adverse reactions. Vial stoppers are not made from natural rubber latex. Testosterone Cypionate Injection (USP) is indicated for replacement therapy in men in conditions associated with symptoms of deficiency or absence of endogenous testosterone.
Testosterone cypionate injection, USP, for intramuscular injection, contains testosterone cypionate, which is the oil-soluble 17 (beta) -cyclopentylpropionate ester of the androgen hormone testosterone. Testosterone in plasma is 98 percent bound to a specific globulin that binds to testosterone and estradiol, and about 2 percent is free. In general, the plasma amount of this sex hormone-binding globulin will determine the distribution of testosterone between the free and bound forms, and the concentration of free testosterone will determine its half-life. In many tissues, testosterone activity appears to depend on the reduction of dihydrotestosterone, which binds to receptor proteins of the cytosol.
There is evidence to suggest that injecting testosterone into some strains of female mice increases their susceptibility to hepatoma. Testosterone is also known to increase the number of tumors and to decrease the degree of differentiation of chemically induced liver carcinomas in rats. Testosterone cypionate is a creamy white or white crystalline powder, odorless or almost odorless and stable in air. Testosterone esters in oil injected intramuscularly are slowly absorbed from the lipid phase; therefore, testosterone cypionate can be administered at intervals two to four weeks.
Testosterone is a controlled substance under the Anabolic Steroid Control Act, and testosterone cypionate injection, USP, has been assigned to Schedule III. Other experts stress that higher doses are needed to induce changes in puberty and that lower doses can be used for maintenance after puberty. About 90 percent of a dose of testosterone is excreted in the urine as conjugates of testosterone and its metabolites with glucuronic and sulfuric acid; about 6 percent of a dose is excreted in the faeces, primarily in conjugated form. During exogenous androgen administration, endogenous testosterone release is inhibited by feedback inhibition of luteinizing hormone pituitary (LH).
Testosterone cypionate should not be used interchangeably with testosterone propionate due to differences in duration of action.
